Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

490 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A report on the diagnosis of intermediate hyperglycemia in Korea: A pooled analysis of four community-based cohort studies.
Oh JY, Lim S, Kim DJ, Kim NH, Kim DJ, Moon SD, Jang HC, Cho YM, Song KH, Ahn CW, Sung YA, Park JY, Shin C, Lee HK, Park KS; Committee of the Korean Diabetes Association on the Diagnosis and Classification of Diabetes Mellitus. Oh JY, et al. Among authors: jang hc. Diabetes Res Clin Pract. 2008 Jun;80(3):463-8. doi: 10.1016/j.diabres.2008.01.022. Epub 2008 Mar 12. Diabetes Res Clin Pract. 2008. PMID: 18339440
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS, Kim JA, Kim SW; Gemigliptin Study 006 Group. Rhee EJ, et al. Among authors: jang hc. Diabetes Obes Metab. 2013 Jun;15(6):523-30. doi: 10.1111/dom.12060. Epub 2013 Jan 30. Diabetes Obes Metab. 2013. PMID: 23320436 Clinical Trial.
Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes.
Hwang YC, Kang M, Ahn CW, Park JS, Baik SH, Chung DJ, Jang HC, Kim KA, Lee IK, Min KW, Nam M, Park TS, Son SM, Sung YA, Woo JT, Park KS, Lee MK. Hwang YC, et al. Among authors: jang hc. Int J Clin Pract. 2013 Mar;67(3):236-43. doi: 10.1111/ijcp.12071. Epub 2013 Jan 22. Int J Clin Pract. 2013. PMID: 23336668 Clinical Trial.
A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise.
Jung CH, Park CY, Ahn KJ, Kim NH, Jang HC, Lee MK, Park JY, Chung CH, Min KW, Sung YA, Park JH, Kim SJ, Lee HJ, Park SW. Jung CH, et al. Among authors: jang hc. Diabetes Metab Res Rev. 2015 Mar;31(3):295-306. doi: 10.1002/dmrr.2613. Epub 2014 Dec 5. Diabetes Metab Res Rev. 2015. PMID: 25362864 Free PMC article. Clinical Trial.
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
Hong S, Park CY, Han KA, Chung CH, Ku BJ, Jang HC, Ahn CW, Lee MK, Moon MK, Son HS, Lee CB, Cho YW, Park SW. Hong S, et al. Among authors: jang hc. Diabetes Obes Metab. 2016 May;18(5):528-32. doi: 10.1111/dom.12631. Epub 2016 Mar 18. Diabetes Obes Metab. 2016. PMID: 26749529 Free PMC article. Clinical Trial.
Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea.
Kim HS, Yu JM, Jang HC, Choi EK, Park JH, Shon HS, Chung CH, Park KG, Cho JH, Kim W, Lee KH, Lee JH, Yoo SJ. Kim HS, et al. Among authors: jang hc. Diabetes Metab Syndr Obes. 2022 May 11;15:1495-1503. doi: 10.2147/DMSO.S334944. eCollection 2022. Diabetes Metab Syndr Obes. 2022. PMID: 35591905 Free PMC article.
490 results